Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Aardvark Therapeutics, Inc. Common Stock

AARD

Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.

Last trade $1.19
Day change -$0.07 (-5.56%)
Day range $1.10 – $1.32
Volume 429,561
Market cap $28M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$27.58M
Price / earnings
—
Price / book
0.48×
Price / sales
—
EV / sales
—
EV / EBITDA
0.43×

Profitability

Earnings per share
-$3.32
Return on assets
-112.28%
Return on equity
-126.3%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
9.11×
Quick ratio
9.11×
Cash ratio
8.58×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$66.81M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for AARD, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025
Revenue$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0
Selling, general and administrative$4.05M$4.63M$5.9M$4.41M$3.97M$2.7M$2.72M
Research and development$15.67M$10.46M$16.57M$14.3M$13.74M$13.15M$7.76M
Total operating expenses$19.72M$15.08M$22.46M$18.7M$17.7M$15.85M$10.47M
Operating income-$19.72M-$15.08M-$22.46M-$18.7M-$17.7M-$15.85M-$10.47M
Interest expense$0$0$0$0$0$0$0
Income before taxes-$19.19M-$14.39M-$21.59M-$17.6M-$16.32M-$14.37M-$9.31M
Income taxes$0$0$0$0$0$0$0
Net income-$19.19M-$14.39M-$21.59M-$17.6M-$16.32M-$14.37M-$9.31M
Net income attributable to common shareholders-$19.19M-$14.39M-$21.59M-$17.6M-$16.32M-$14.37M-$9.31M
EBITDA-$19.71M-$15.07M-$22.45M-$18.69M-$17.69M-$15.84M-$10.47M
Basic earnings per share-$0.88-$0.66-$0.99-$0.80-$0.75-$0.66-$0.71
Diluted earnings per share-$0.88-$0.66-$0.99-$0.80-$0.75-$0.66-$0.71

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Aardvark Therapeutics Reports Exploratory Data from the Terminated HERO and Open-Label Extension Trials

Aardvark Therapeutics reported exploratory efficacy data from its early-terminated Phase 3 HERO trial for ARD-101, a hunger-suppressing therapy for Prader-Willi syndrome. The drug showed modest reductions in hyperphagia scores and was generally well-tolerated, though one cardiac serious adverse event occurred at the highest dose in combination with another drug. The FDA lifted the clinical hold, allowing the company to resume development at lower doses and plan a new Phase 3 trial.

Zacks Investment Research

All You Need to Know About Aardvark Therapeutics, Inc. (AARD) Rating Upgrade to Buy

Aardvark Therapeutics, Inc. (AARD) has been upgraded to a Zacks Rank #2 (Buy) rating due to rising earnings estimates over the past three months, with consensus estimates increasing 12.4%. The upgrade reflects improved business fundamentals and positions the stock in the top 20% of Zacks-covered stocks, suggesting potential for near-term price appreciation.

GlobeNewswire Inc.

AARD DEADLINE NOTICE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important October 13 Deadline in Securities Class Action – AARD

Rosen Law Firm is notifying investors in Aardvark Therapeutics, Inc. of an October 13, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that Aardvark made materially false and misleading statements regarding the safety and prospects of its drug ARD-101, and failed to disclose material adverse facts about the company's business and operations.

GlobeNewswire Inc.

AARD 截止日期通知:知名律師事務所 ROSEN 提醒 Aardvark Therapeutics, Inc. 投資人,應於證券集體訴訟重要期限 10 月 13 日之前委任法律律師 – AARD

Rosen Law Firm reminds investors in Aardvark Therapeutics who purchased securities during the IPO on February 13, 2025 through May 14, 2026 of an October 13, 2026 deadline to nominate a lead plaintiff. The lawsuit alleges that defendants made material false and misleading statements regarding the safety and commercial prospects of ARD-101, causing investor losses when the truth was revealed.

GlobeNewswire Inc.

URGENT AARDVARK DEADLINE: Bragar Eagel & Squire, P.C. Urges Aardvark Therapeutics, Inc. Investors to Contact the Firm Seeking Lead Plaintiff Role Before October 13th

A class action lawsuit has been filed against Aardvark Therapeutics in the U.S. District Court for the Southern District of California. The lawsuit alleges that defendants made materially false and misleading statements in the company's IPO registration statement and throughout the class period (February 13, 2025 to May 14, 2026), specifically regarding the safety and commercial prospects of their drug ARD-101. Investors who purchased shares during this period can apply to be lead plaintiff by October 13, 2026.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Jul 21, 20081-for-2reverse split